Curevo
Bothell
About Curevo
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $196.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2025)
- Website: curevovaccine.com
- Phone: 1(206)492-5722
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/curevo-93421 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.